ArticleFrontiers in molecular biosciences2025
Identification of key genes CCL5, PLG, LOX and C3 in clear cell renal cell carcinoma through integrated bioinformatics analysis.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK‑STAT pathway.Oncology reports · 2026Article
- A multi-omics prognostic model and functional validation ofTranslational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear Cell Renal Cell Carcinoma (ccRCC) is a malignant tumor with high mortality and recurrence rates and the molecular mechanism of ccRCC genesis remains unclear. In this study, we identified several key genes associated with the prognosis of ccRCC by using integrated bioinformatics. Methods: Two ccRCC expression profiles were downloaded from Gene Expression Omnibus and one dataset was gained from The Cancer Genome Atlas The Robust Rank Aggregation method was used to analyze the three datasets to gain integrated differentially expressed genes The Gene Ontology and KEGG analysis were performed to explore the potential functions of DEGs. The Search Tool for the Retreival of Interacting Genes/Proteins (STRING) and Cytoscape software were used to construct protein-protein interaction network and module analyses to screen the hub genes. Spearman's correlation analysis was conducted to evaluate the interrelationships among the hub genes. The prognostic value was evaluated through K-M survival analysis, Cox regression analysis, and receiver operating characteristic curve analysis to determine their potential as prognostic biomarkers in ccRCC. The expression of hub genes between ccRCC and adjacent normal tissues was analyzed by RT-qPCR, Western blotting, and immunohistochemical (IHC). Result: 125 DEGs were identified using the limma package and RRA method, including 62 up-expressed genes and 63 down-expressed genes. GO and KEGG analysis showed some associated pathways. Spearman's correlation analysis revealed that the hub genes are not only interrelated but also closely associated with immune cell infiltration. Gene expression analysis of the hub genes based on the TCGA-KIRC cohort, along with K-M survival analysis, Cox regression, and ROC curve analysis, consistently demonstrated that CCL5, LOX, and C3 are significantly upregulated in ccRCC and are associated with poor clinical outcomes. In contrast, PLG showed opposite result. These results were further validated at the mRNA and protein levels. Conclusion: Our findings indicate that CCL5, LOX, C3, and PLG are significantly associated with the progression and prognosis of ccRCC, highlighting their potential as prognostic biomarkers. These results provide a foundation for future research aimed at uncovering the underlying mechanisms and identifying potential therapeutic targets for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.